Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP

Biomarkers. 2015;20(4):253-7. doi: 10.3109/1354750X.2015.1068855.

Abstract

Objective: To investigate the expression and prognostic value of miR-224 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent R-CHOP.

Materials and methods: RT-PCR was used to determine the relative expression of miR-224, in 258 DLBCL patients and 40 normal lymphoid tissue specimens.

Results: MiR-224 expression in DLBCL patients was significantly down-regulated compared to that in negative controls (p < 0.05). The 5-year progression-free survival and overall survival rates were significantly higher in the high-expression level group compared to the low-expression level group (p < 0.05).

Conclusions: MiR-224 expression level is implicated as a prognostic marker for DLBCL patients treated with R-CHOP.

Keywords: Biomarkers; R-CHOP; diffuse large B-cell lymphoma; microRNA.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • MicroRNAs / genetics*
  • Middle Aged
  • Neoplasm Staging
  • Prednisone / administration & dosage
  • Prognosis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome
  • Vincristine / administration & dosage
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers, Tumor
  • MIRN224 microRNA, human
  • MicroRNAs
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone